170 related articles for article (PubMed ID: 24529061)
1. Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.
Trinkaus ME; Hicks RJ; Young RJ; Peters LJ; Solomon B; Bressel M; Corry J; Fisher R; Binns D; McArthur GA; Rischin D
J Med Imaging Radiat Oncol; 2014 Feb; 58(1):89-97. PubMed ID: 24529061
[TBL] [Abstract][Full Text] [Related]
2. Insights into the relationship between HPV/p16 status, hypoxia imaging and treatment outcomes in head and neck cancer.
Porceddu SV
J Med Imaging Radiat Oncol; 2014 Feb; 58(1):98-100. PubMed ID: 24529062
[No Abstract] [Full Text] [Related]
3. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
Rischin D; Hicks RJ; Fisher R; Binns D; Corry J; Porceddu S; Peters LJ;
J Clin Oncol; 2006 May; 24(13):2098-104. PubMed ID: 16648512
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
6. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
Kikuchi M; Koyasu S; Shinohara S; Usami Y; Imai Y; Hino M; Itoh K; Tona R; Kanazawa Y; Kishimoto I; Harada H; Naito Y
Head Neck; 2015 Oct; 37(10):1524-31. PubMed ID: 24890445
[TBL] [Abstract][Full Text] [Related]
8. Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy.
Bittner MI; Wiedenmann N; Bucher S; Hentschel M; Mix M; Rücker G; Weber WA; Meyer PT; Werner M; Grosu AL; Kayser G
Acta Oncol; 2016 Nov; 55(11):1299-1304. PubMed ID: 27593107
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
10. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
11. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
12. Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma.
Clark J; Jeffery CC; Zhang H; Cooper T; O'Connell DA; Harris J; Seikaly H; Biron VL
J Otolaryngol Head Neck Surg; 2015 Sep; 44(1):37. PubMed ID: 26374294
[TBL] [Abstract][Full Text] [Related]
13. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.
Hicks RJ; Rischin D; Fisher R; Binns D; Scott AM; Peters LJ
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1384-91. PubMed ID: 16133382
[TBL] [Abstract][Full Text] [Related]
14. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
[TBL] [Abstract][Full Text] [Related]
15. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224).
Saksø M; Mortensen LS; Primdahl H; Johansen J; Kallehauge J; Hansen CR; Overgaard J
Radiother Oncol; 2020 Oct; 151():126-133. PubMed ID: 32805273
[TBL] [Abstract][Full Text] [Related]
16. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy.
Bittner MI; Wiedenmann N; Bucher S; Hentschel M; Mix M; Weber WA; Grosu AL
Radiother Oncol; 2013 Sep; 108(3):511-6. PubMed ID: 23849686
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus, p16, and epidermal growth factor receptor biomarkers and CT perfusion values in head and neck squamous cell carcinoma.
Hoefling NL; McHugh JB; Light E; Kumar B; Walline H; Prince M; Bradford C; Carey TE; Mukherji SK
AJNR Am J Neuroradiol; 2013 May; 34(5):1062-6, S1-2. PubMed ID: 23370473
[TBL] [Abstract][Full Text] [Related]
18. p16 expression in cutaneous squamous cell carcinoma of the head and neck is not associated with integration of high risk HPV DNA or prognosis.
Satgunaseelan L; Chia N; Suh H; Virk S; Ashford B; Lum T; Ranson M; Clark J; Gupta R
Pathology; 2017 Aug; 49(5):494-498. PubMed ID: 28663082
[TBL] [Abstract][Full Text] [Related]
19. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - A DAHANCA 19 study.
Kristensen MH; Sørensen MK; Tramm T; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Lilja-Fischer JK; Holm AIS; Samsøe E; Hansen CR; Zukauskaite R; Overgaard J; Eriksen JG
Radiother Oncol; 2024 Apr; 193():110149. PubMed ID: 38341096
[TBL] [Abstract][Full Text] [Related]
20. Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma.
Young RJ; Urban D; Angel C; Corry J; Lyons B; Vallance N; Kleid S; Iseli TA; Solomon B; Rischin D
Br J Cancer; 2015 Mar; 112(6):1098-104. PubMed ID: 25688737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
